E. Hagg et al., Magnesium therapy in type 1 diabetes. A double blind study concerning the effects on kidney function and serum lipid levels, MAGNES RES, 12(2), 1999, pp. 123-130
To test the hypothesis that magnesium depletion might be of importance for
the development of vascular complications in diabetes mellitus we performed
a randomized, double-blind, placebo-controlled study during 12 months with
20-30 mmol/day of oral magnesium hydroxide in 28 type 1 diabetic patients.
Urinary albumin excretion, Cr-EDTA-clearance and certain blood cardiovascu
lar risk factors were measured. At the end of the study there were no signi
ficant differences of these parameters between the two groups, except that
serum triglyceride values increased in three magnesium treated patients who
either showed an increase in blood glycosylated hemoglobin values or body
weight during the study.